Amendments to the Claims

- 1. (Cancelled)
- (Cancelled)
- (Cancelled)
- 4. (Cancelled)
- 5. (Cancelled)
- (Cancelled)
- (Cancelled)
- 8. (Cancelled)
- 9. (Cancelled)
- 10. (Currently Amended) A compound selected from the group consisting of:
- 4-[4-(2-Methylamino-ethyl)-phenoxy]-phenol,
- 4-{4-[2-(Benzyl-methyl-amino)-ethyl]-phenoxy}-phenol,

Acetic acid 4-[4-(2-benzylamino-ethyl)-phenoxy]-phenyl ester,

- 6-[4-(Benzylamino-methyl)-phenylsulfanyl]-nicotinamide,
- 6-{4-[(3-Methyl-butylamino)-methyl]-phenylsulfanyl}-nicotinamide.
- 6-{4-[(2-Pvridin-4-vl-ethylamino)-methyl]-phenylsulfanyl}-nicotinamide.
- 6-[4-(Phenethylamino-methyl)-phenylsulfanyl]-nicotinamide,
- 6-{4-[(Cyclopropylmethyl-amino)-methyl]-phenylsulfanyl}-nicotinamide.
- 6-{4-[(2-Thiophen-2-vl-ethylamino)-methyl]-phenylsulfanyl}-nicotinamide.
- 6-{4-[(3-Phenyl-propylamino)-methyl]-phenylsulfanyl}-nicotinamide,
- 6-{4-[(3-Methyl-butylamino)-methyl]-phenylsulfanyl}-nicotinamide,
- 4-[4-(Phenethylamino-methyl)-benzenesulfonyl]-benzamide,
- 4-[4-(Phenethylamino-methyl)-benzenesulfinyl]-benzamide,
- 6-[4-(2-Benzylamino-ethyl)-phenylamino]-nicotinamide,
- 6-{4-[2-(Cyclohexylmethyl-amino)-ethyl]-phenylamino}-nicotinamide,
- 6-{4-[(2-Pyridin-4-yl-ethylamino)-methyl]-phenylsulfanyl}-nicotinamide,
- 6-[4-(Benzylamino-methyl)-phenylamino]-nicotinamide,
- 6-{4-[(Cyclohexylmethyl-amino)-methyl]-phenylamino}-nicotinamide,
- 6-[4-(Phenethylamino-methyl)-phenylamino]-nicotinamide,
- 6-{4-[(3-Methyl-butylamino)-methyl]-phenylamino}-nicotinamide,

N-{4-[4-(2-Benzylamino-ethyl)-phenoxy]-phenyl}-acetamide,

N-{4-[4-(2-Hexylamino-ethyl)-phenoxy]-phenyl}-acetamide,

N-[4-(4-{2-[(Thiophen-2-vlmethyl)-amino]-ethyl}-phenoxy)-phenyl]-acetamide,

N-(4-{4-[2-(3-Phenyl-propylamino)-ethyl]-phenoxy}-phenyl)-acetamide.

N-(4-{4-[2-(2-Cyclohexyl-ethylamino)-ethyl]-phenoxy}-phenyl)-acetamide.

N-{4-[4-(2-Phenethylamino-ethyl)-phenoxyl-phenyl}-acetamide.

N-{4-[4-(2-Propylamino-ethyl)-phenoxy]-phenyl}-acetamide,

N-{4-[4-(2-Pentylamino-ethyl)-phenoxy]-phenyl}-acetamide,

N-(4-{4-[2-(Cyclohexylmethyl-amino)-ethyl]-phenoxy}-phenyl)-acetamide,

N-(4-{4-[2-(2-Trifluoromethyl-benzylamino)-ethyl]-phenoxy}-phenyl)-acetamide,

N-[4-(4-{2-[(Furan-2-ylmethyl)-amino]-ethyl}-phenoxy)-phenyl]-acetamide,

N-(4-{4-[2-(3-Chloro-benzylamino)-ethyl]-phenoxy}-phenyl)-acetamide.

4-[4-(2-Benzylamino-ethyl)-phenoxyl-phenylamine.

N-{4-[4-(2-Benzylamino-ethyl)-phenoxy]-phenyl}-benzamide,

Morpholine-4-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxyl-phenyl}-amide.

N-{4-[4-(2-Benzylamino-ethyl)-phenoxy]-phenyl}-2-methoxy-acetamide,

Furan-2-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxyl-phenyl}-amide.

Isoxazole-5-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxy]-phenyl}-amide,

Thiophene-2-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxyl-phenyl}-amide.

N-{4-[4-(2-Benzylamino-ethyl)-phenoxy]-phenyl}-isonicotinamide,

3,5-Dimethyl-isoxazole-4-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxy]-phenyl}-amide.

2-tert-Butyl-5-methyl-2H-pyrazole-3-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxy]-phenyl}-amide,

5-Methyl-isoxazole-3-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxy]-phenyl}-amide,

4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxy]-phenvl}-amide,

phonji, umiac,

N-{4-[4-(2-Benzylamino-ethyl)-phenoxy]-phenyl}-3-methylsulfanyl-propionamide,

Ouinoxaline-2-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxyl-phenyl}-amide,

N-{4-[4-(2-Benzylamino-ethyl)-phenoxy]-phenyl}-nicotinamide,

Pyridine-2-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxy]-phenyl}-amide,

N-(6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-pyridin-3-yl)-acetamide,

or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer and diastereomeric mixtureor solvate thereof.

- (Currently Amended) A pharmaceutical composition comprising a
 therapeutically effective amount of a compound according to any one of Claims 1 to 10Claim
 10 in association with a carrier, diluent and/or excipient.
 - 12. (Cancelled)
 - (Cancelled)
 - (Cancelled)
 - 15. (Cancelled)
 - 16. (Cancelled)
 - 17. (Cancelled)
 - (New) A compound selected from the group consisting of:
- [2-(4-Hydroxy-phenyl)-ethyl]-carbamic acid ethyl ester
- {2-[4-(4-Cyano-phenoxy)-phenyl]-ethyl}-carbamic acid ethyl ester
- {2-[4-(4-Acetyl-phenoxy)-phenyl]-ethyl}-carbamic acid ethyl ester

Acetic acid 4-[4-(2-ethoxycarbonylamino-ethyl)-phenoxyl-phenyl ester

- 4-(2-Benzylamino-ethyl)-phenol
- 4-[4-(2-Benzylamino-ethyl)-phenoxyl-benzonitrile
- 1-{4-[4-(2-Benzylamino-ethyl)-phenoxyl-phenyl}-ethanone
- 6-(4-Cvanomethyl-phenylamino)-nicotinamide
- 6-[4-(2-Amino-ethyl)-phenylamino]-nicotinamide
- [2-(4-Hydroxy-phenyl)-ethyl]-carbamic acid tert-butyl ester
- {2-[4-(4-Nitro-phenoxy)-phenyl]-ethyl}-carbamic acid tert-butyl ester
- {2-[4-(4-Amino-phenoxy)-phenyl]-ethyl}-carbamic acid tert-butyl ester
- {2-[4-(4-Acetylamino-phenoxy)-phenyl]-ethyl}-carbamic acid tert-butyl ester
- N-{4-[4-(2-Amino-ethyl)-phenoxy]-phenyl}-acetamide
- N-{4-[4-(2-Isobutylamino-ethyl)-phenoxy]-phenyl}-acetamide
- N-{4-[4-(2-Cyclohexylamino-ethyl)-phenoxy]-phenyl}-acetamide
- N-(4-{4-[2-(2-Methyl-benzylamino)-ethyl]-phenoxy}-phenyl)-acetamide
- N-(4-{4-[2-(3-Fluoro-benzylamino)-ethyl]-phenoxy}-phenyl)-acetamide

 $N-[4-(4-\{2-[(3-Methyll-thiophen-2-ylmethyl)-amino]-ethyl\}-phenoxy)-phenyl]-acetamide $N-(4-\{4-[2-(3-Methyl-butylamino)-ethyl]-phenoxy\}-phenyl)-acetamide $N-(4-\{4-[2-(3,5-Difluoro-benzylamino)-ethyl]-phenoxy\}-phenyl)-acetamide $N-(4-\{4-[2-(3,5-Difluoro-benzylamino)-ethyl]-phenoxy\}-phenyl)-acetamide $N-(4-\{4-[2-(3,5-Difluoro-benzylamino)-ethyl]-phenoxy]-phenyl)-acetamide $N-(4-\{4-[2-(3,5-Difluoro-benzylamino)-ethyl]-phenoxy]-phenyl)-acetamide $N-(4-\{4-[4-(3,5-Difluoro-benzylamino)-ethyl]-phenoxy]-phenyl)-acetamide $N-(4-\{4-[4-(3,5-Difluoro-benzylamino)-ethyl]-phenoxy]-phenyl]$

 $N-[4-(4-\{2-[(Pyridin-3-ylmethyl)-amino]-ethyl\}-phenoxy)-phenyl]-acetamide$

 $\hbox{$4$-[4-(2-Benzylaminoethyl)phenoxy]} benzenesul fon a mide$

6-(4-Cyano-benzyl)-nicotinamide

or a pharmaceutically acceptable salt or solvate thereof.

 (New) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 18 in association with a carrier, diluent and/or excipient.